El Centro de Investigación Hemato Oncológico (CIHO) aims to promote and develop clinical research in hemato-oncology, for which it has a multidisciplinary group of health professionals in the areas of hematology, oncology, pathology, surgery, molecular biology, epidemiology , infectology, among others.
Our principle is to foster a culture of research and scientific dissemination based on critical, ethical and responsible thinking, aimed at the contribution of knowledge, continuous improvement and innovation in the methods of diagnosis, treatment and care of our users and their families.
The CIHO develops clinical research projects of its own initiative and also collaborates in protocols financed by external institutions such as Colciencias, universities, institutes or the pharmaceutical industry. We currently have research collaborations with groups belonging to the Universidad Libre, Universidad del Valle, University of Antioquia and the International Center for Studies in Human Genetics CIDEGEN of Salamanca, Spain.
Similarly, CIHO participates in clinical research protocols funded by pharmaceutical companies such as Roche, Novartis, Janssen, Sanofi, Glaxo Smith Kline, among others. These research protocols include multicenter controlled clinical trials that assess the efficacy or safety of new drugs for the treatment of cancer or hematological diseases which in Colombia can only be performed by institutions that have been certified by the INVIMA in Good Clinical Practices (BPC). / GCP) according to resolution 2378 of 2008, certification with which the CIHO has had since 2012.